[go: up one dir, main page]

WO1999007352A3 - Method for promoting expression of ldl receptor gene - Google Patents

Method for promoting expression of ldl receptor gene Download PDF

Info

Publication number
WO1999007352A3
WO1999007352A3 PCT/JP1998/003595 JP9803595W WO9907352A3 WO 1999007352 A3 WO1999007352 A3 WO 1999007352A3 JP 9803595 W JP9803595 W JP 9803595W WO 9907352 A3 WO9907352 A3 WO 9907352A3
Authority
WO
WIPO (PCT)
Prior art keywords
unsubstituted
substituted
ldl receptor
receptor gene
promoting expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1998/003595
Other languages
French (fr)
Other versions
WO1999007352A2 (en
Inventor
Yoshihide Ueno
Koji Morishita
Masami Muraoka
Naohito Ohashi
Bei Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Tularik Inc
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Tularik Inc filed Critical Sumitomo Pharmaceuticals Co Ltd
Priority to AU86476/98A priority Critical patent/AU8647698A/en
Publication of WO1999007352A2 publication Critical patent/WO1999007352A2/en
Publication of WO1999007352A3 publication Critical patent/WO1999007352A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Method of promoting expression of LDL receptor gene and an agent therefor, which comprises as an active ingredient a 1,2,4-triazin-5-one derivative of formula (I), wherein R1 is unsubstituted or substituted phenyl, unsubstituted or substituted heterocycle; R2 is unsubstituted or substituted phenyl, unsubstituted or substituted naphthyl, unsubstituted or substituted aralkyl, unsubstituted or substituted 5- to 6-membered aromatic heteromonocycle, unsubstituted or substituted C¿1?-C6alkyl, or unsubstituted or substituted C2-C6alkenyl, or pharmaceutically acceptable salt thereof, said active compound (I) increasing the LDL receptor amount by promoting expression of LDL receptor gene (amount of mRNA), by which showing activity of reducing cholesterol level in the blood, and therefore being useful in the prophylaxis or treatment of hyperlipidemia.
PCT/JP1998/003595 1997-08-12 1998-08-12 Method for promoting expression of ldl receptor gene Ceased WO1999007352A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU86476/98A AU8647698A (en) 1997-08-12 1998-08-12 Method of promoting expression of ldl receptor gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5571297P 1997-08-12 1997-08-12
JP60/055,712 1997-08-12

Publications (2)

Publication Number Publication Date
WO1999007352A2 WO1999007352A2 (en) 1999-02-18
WO1999007352A3 true WO1999007352A3 (en) 1999-05-14

Family

ID=21999680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/003595 Ceased WO1999007352A2 (en) 1997-08-12 1998-08-12 Method for promoting expression of ldl receptor gene

Country Status (3)

Country Link
JP (1) JPH11106378A (en)
AU (1) AU8647698A (en)
WO (1) WO1999007352A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002226464A (en) * 2001-01-30 2002-08-14 Sumitomo Pharmaceut Co Ltd Triaryl analogs and uses thereof
WO2025016381A1 (en) * 2023-07-17 2025-01-23 Laekna Therapeutics Shanghai Co., Ltd. Triazine compounds and their use as usp1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343801A (en) * 1979-12-03 1982-08-10 Sumitomo Chemical Company, Limited 1,2,4-Triazine derivatives, and their production and use
WO1990000897A1 (en) * 1988-07-27 1990-02-08 University Of North Carolina At Chapel Hill Method for the control of hyperlipidemia
WO1998042686A1 (en) * 1997-03-24 1998-10-01 Sumitomo Pharmaceuticals Company, Limited Ldl receptor gene expression promoters

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343801A (en) * 1979-12-03 1982-08-10 Sumitomo Chemical Company, Limited 1,2,4-Triazine derivatives, and their production and use
WO1990000897A1 (en) * 1988-07-27 1990-02-08 University Of North Carolina At Chapel Hill Method for the control of hyperlipidemia
WO1998042686A1 (en) * 1997-03-24 1998-10-01 Sumitomo Pharmaceuticals Company, Limited Ldl receptor gene expression promoters

Also Published As

Publication number Publication date
AU8647698A (en) 1999-03-01
JPH11106378A (en) 1999-04-20
WO1999007352A2 (en) 1999-02-18

Similar Documents

Publication Publication Date Title
HU9500240D0 (en) New prolin-amide derivatives and pharmaceutical compositions containing them as active component
CA2268129A1 (en) 1,2,3-thiadiazole derivatives or salts thereof and agrohorticultural disease controller and method for using the same
WO2000071510A3 (en) INHIBITORS OF FACTOR Xa
WO2001019788A3 (en) BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
AU6500298A (en) Derivatives of azetidine and pyrrolidine
AU5910996A (en) Pyrrole derivatives and medicinal composition
AU2231797A (en) Novel iridoid derivatives and a vascularization inhibitor having for its active ingredient said derivative
AU4396899A (en) Remedies for diabetes
WO2003063791A3 (en) Non-steroidal analogs of 2-methoxyestradiol
WO1999012570A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1999007352A3 (en) Method for promoting expression of ldl receptor gene
EP1008345A4 (en) Antiallergic agents
EP1043311A4 (en) Biphenylamidine derivatives
AU1893001A (en) Skin external agents and drugs
AU6889096A (en) Pyrimidine derivatives
DE69828390D1 (en) DIAMINOTRIFLUOROMETHYLPYRIMIDIN DERIVATIVES ANTICREASIC COMPOSITION
DE60027204D1 (en) Benzamidinderivate
AU7935887A (en) Therapeutic agent for the treatment of peptic ulcer disease
ATE126213T1 (en) PYRROLALDEHYDE DERIVATIVES.
EP0711554A4 (en) Antidepressant
WO2003073985A3 (en) New methods of using antiangiogenic agents
EP1099440A4 (en) Therapeutic agents
AU1733101A (en) Benzamidine derivatives
BR0014319A (en) Pyrimidine derivatives, process for preparing derivatives and drugs containing the same as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09485322

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA